BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer BMS#CA225091.

Trial Profile

BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer BMS#CA225091.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2013

At a glance

  • Drugs Carboplatin; Cetuximab; Paclitaxel
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2013 New source identified and integrated: ClinialTrials.gov record NCT01904435.
    • 29 Jul 2013 New source identified and integrated: ClinialTrials.gov record NCT01904435.
    • 26 May 2010 Actual end date (April 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top